Pharmacokinetic Study of Coadministration with Cefuroxime Sodium for Injection Influencing ReDuNing Injection-Derived Seven Phytochemicals and Nine Metabolites in Rats
Table 6
The pharmacokinetic parameters of the compounds in rat plasma after intravenous coadministration of RDN and CNa.
Compound
Group
AUC(0-t)
T1/2
Cmax
CL
(ng/mL h)
(h)
(ng/mL)
(L/h/kg)
Geniposide
1 (RDN-1)
15882 ± 2455
0.50 ± 0.13
42673 ± 3368
1266 ± 181
3 (RDN/CNa-1)
13576 ± 568a
0.27 ± 0.03a
31243 ± 3242a
1461 ± 64a
4 (RDN-5)
10735 ± 1306
0.36 ± 0.03
31584 ± 5073
1639 ± 215
5 (CNA-4 + RDN-1)
8870 ± 541d
0.23 ± 0.05d
24702 ± 3662d
2129 ± 204d
6 (RDN/CNA-4 + RDN-1)
4590 ± 604e
0.21 ± 0.02e
18042 ± 2915e
4268 ± 580e
8 (RDN/CNA-5)
10482 ± 1137c
0.17 ± 0.07b,c
35357 ± 4441
1871 ± 237c
Shanzhiside
1 (RDN-1)
2926 ± 423
0.40 ± 0.04
4816 ± 908
193 ± 28
3 (RDN/CNA-1)
2318 ± 216a
0.58 ± 0.08a
4124 ± 324
218 ± 43
4 (RDN-5)
3089 ± 463
0.53 ± 0.10
4972 ± 578
175 ± 27
5 (CNA-4 + RDN-1)
2251 ± 238d
0.26 ± 0.03d
3344 ± 541d
231 ± 47d
6 (RDN/CNA-4 + RDN-1)
1392 ± 132e
0.38 ± 0.04e
2920 ± 202e
405 ± 40e
8 (RDN/CNA-5)
1503 ± 104b,c
0.63 ± 0.09
3358 ± 643b,c
356 ± 23b,c
Genipin-1-β-gentiobioside
1 (RDN-1)
5454 ± 515
0.29 ± 0.07
17337 ± 2898
1802 ± 219
3(RDN/CNA-1)
5025 ± 648
0.17 ± 0.03a
11673 ± 964a
2092 ± 261
4 (RDN-5)
4878 ± 360
0.17 ± 0.03
14540 ± 1994
1757 ± 333
5 (CNA-4 + RDN-1)
2844 ± 340d
0.41 ± 0.17d
7593 ± 1412d
3084 ± 651d
6 (RDN/CNA-4 + RDN-1)
1894 ± 270e
0.23 ± 0.04e
8800 ± 1676e
5102 ± 873e
8 (RDN/CNA-5)
3010 ± 245b,c
0.24 ± 0.03b,c
11448 ± 1954b
2857 ± 786b,c
Secoxyloganin
1 (RDN-1)
4363 ± 481
0.34 ± 0.07
15334 ± 3324
466 ± 49
3 (RDN/CNA-1)
4319 ± 647
0.50 ± 0.14a
13063 ± 1283
347 ± 72a
4 (RDN-5)
4414 ± 454
0.40 ± 0.08
12893 ± 2938
431 ± 33
5 (CNA-4 + RDN-1)
3056 ± 369d
0.29 ± 0.10
8625 ± 1680d
546 ± 110d
6 (RDN/CNA-4 + RDN-1)
2291 ± 293e
0.35 ± 0.04
10509 ± 1878
785 ± 82e
8 (RDN/CNA-5)
2982 ± 337b,c
0.27 ± 0.06b,c
10878 ± 2123
645 ± 98b,c
Neochlorogenic acid
1 (RDN-1)
3432 ± 541
0.16 ± 0.03
17113 ± 2866
2223 ± 293
3 (RDN/CNA-1)
6631 ± 443a
0.15 ± 0.06
21577 ± 2564a
1172 ± 89a
4 (RDN-5)
4639 ± 413
0.23 ± 0.10
22059 ± 2157
1528 ± 205
5(CNA-4 + RDN-1)
1401 ± 191d
0.25 ± 0.05
6228 ± 1209d
4958 ± 626
6 (RDN/CNA-4 + RDN-1)
1762 ± 240e
0.13 ± 0.02e
10871 ± 1093e
4310 ± 505.1e
8 (RDN/CNA-5)
3259 ± 301b,c
0.15 ± 0.02
15385 ± 2881b,c
2350 ± 202b,c
Chlorogenic acid
1 (RDN-1)
2973 ± 307
0.35 ± 0.20
12047 ± 2071
3378 ± 562
3 (RDN/CNA-1)
6350 ± 420a
0.22 ± 0.10
25083 ± 3526a
1758 ± 240a
4 (RDN-5)
5614 ± 644
0.14 ± 0.03
25312 ± 3764
2190 ± 294
5 (CNA-4 + RDN-1)
1018 ± 134d
0.13 ± 0.02
5077 ± 965d
12262 ± 1517d
6 (RDN/CNA-4 + RDN-1)
1639 ± 263e
0.17 ± 0.04
9417 ± 1926e
7507 ± 1183e
8 (RDN/CNA-5)
3998 ± 341b,c
0.16 ± 0.06
22140 ± 1861
3038 ± 327b,c
Cryptochlorogenic acid
1 (RDN-1)
2358 ± 249
0.24 ± 0.04
9650 ± 1207
3039 ± 325
3 (RDN/CNA-1)
5080 ± 265a
0.21 ± 0.06
19946 ± 3024a
1426 ± 142a
4 (RDN-5)
4824 ± 577
0.19 ± 0.03
18894 ± 2701
1554 ± 185
5 (CNA-4 + RDN-1)
894 ± 97d
0.21 ± 0.06
3856 ± 565d
8353 ± 1052d
6 (RDN/CNA-4 + RDN-1)
1424 ± 192e
0.19 ± 0.01
7679 ± 1253e
5421 ± 768e
8 (RDN/CNA-5)
3100 ± 370b,c
0.15 ± 0.06
16484 ± 2279c
2551 ± 396b,c
Cefuroxime
2 (CNa-1)
258567 ± 16978
0.36 ± 0.05
318320 ± 34982
780 ± 111
3 (RDN/CNa-1)
199337 ± 14691f
0.41 ± 0.05
358284 ± 31456
1095 ± 94f
7 (CNa-5)
197432 ± 16765
0.27 ± 0.09
492963 ± 47916
1136 ± 93
8 (RDN/CNa-5)
184016 ± 17314
0.25 ± 0.04
438024 ± 81058
1226 ± 119
a, Group 1 vs Group 3; b, Group 3 vs Group 6; c, Group 2 vs Group 6; d, Group 3 vs Group 4; e; Group 3 vs Group 5 and f; Group 2 vs Group 7.